加载中
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
常规交易时段
US$2.275
−US$0.175 · -7.14%
盘中时间采用ET。市场数据可能有所延迟。
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
日内区间
当前US$2.275
52周区间
当前US$2.275
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
47
合理估值
情绪
44
多空交织
风险
62
高风险
动量
34
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
日内区间
当前US$2.275
52周区间
当前US$2.275
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 4037.4万 USD | 8000.1万 USD | 2.5亿 USD | 4090.7万 USD | 3741.5万 USD |
| 销货成本 | 1.32亿 USD | — | 9217.2万 USD | 5576.4万 USD | 7378.7万 USD |
| 毛利 | −9190万 USD | 8000.1万 USD | 1.58亿 USD | −1485.7万 USD | −3637.2万 USD |
| 研究与开发 | 1.35亿 USD | 1.27亿 USD | 9217.2万 USD | 6076.4万 USD | 7378.7万 USD |
| 销售、一般及管理费用 | 3644.4万 USD | 3592万 USD | 3582.2万 USD | 3098万 USD | 3724.6万 USD |
| 营业费用 | 3994.4万 USD | 1.63亿 USD | 3582.2万 USD | 3598万 USD | 3724.6万 USD |
| 利息收入 | 1061.8万 USD | 1832.8万 USD | 1172.1万 USD | 179.2万 USD | — |
| 折旧和摊销 | 406万 USD | 473.1万 USD | 444.1万 USD | 619.1万 USD | 516.5万 USD |
| 营业利润 | −1.32亿 USD | −8328.7万 USD | 1.22亿 USD | −5083.7万 USD | −7361.8万 USD |
| 净利润 | −1.2亿 USD | −6500.2万 USD | 1.32亿 USD | −4640.8万 USD | −7119.7万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$14.40
上涨空间 532.97%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI576.8万0.00%2.3万亿 USD0.03%US$381.28-0.17%
iShares Russell 2000 ETFIWM341.7万0.00%787.4亿 USD0.19%US$278.21-0.26%
Vanguard Extended Market ETFVXF211.53万0.00%954亿 USD0.05%US$233.72-0.55%
Vanguard Russell 2000 ETFVTWO104.38万0.01%180亿 USD0.06%US$112.38-0.25%
iShares Biotechnology ETFIBB93.83万0.01%108.2亿 USD0.44%US$204.56-0.94%
Dimensional - US Small Cap ETFDFAS69.56万0.00%338.69亿 USD0.31%US$78.34-0.01%
Fidelity Enhanced Small Cap ETFFESM40.96万0.01%64.1亿 USD0.28%US$45.325-0.30%
iShares Micro-Cap ETFIWC40.33万0.03%13.17亿 USD0.60%US$182.13-0.48%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASFidelity Enhanced Small Cap ETFFESMiShares Micro-Cap ETFIWCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
